HealthCare Investors Meeting March 31, 2026

Where Healthcare Innovation Meets Capital Markets

Bern, 11/02/2026 - The Swiss healthcare sector is moving back into the spotlight of the capital markets. To provide institutional and professional investors with a focused and high-quality overview of listed companies and potential IPO candidates, schweizeraktien.net will host the HealthCare Investors Meeting on March 31, 2026, at the Genolier Innovation Hub.

The industry event is organized in cooperation with AEVIS Victoria and the French-speaking Swiss business newspaper AGEFI. Company presentations, panel discussions and networking opportunities will foster in-depth dialogue between corporates, investors and capital market professionals.

At the conference center of Clinique Genolier, the listed companies Basilea, BioVersys, Galenica, PolyPeptide, Medacta and AEVIS Victoria will present their strategies, operational progress and upcoming value drivers. Senior management will be available for Q&A sessions and one-on-one meetings.

A special focus will be on the Private Track, organized with the support of SIX Swiss Exchange. AB2 Bio, CUTISS, OM Pharma and Topadur Pharma will introduce themselves as high-growth businesses that may become future IPO candidates.

An accompanying panel will address venture capital, capital markets readiness and the requirements for going public.

For further information and registration, please visit investorsmeeting.ch.

The event is supported by the Genolier Innovation Hub, Kellerhals Carrard, SIX Swiss Exchange, Citi and AGEFI as media partner.

Media contact

Björn Zern, Co-Founder
schweizeraktien.net ag
bjoern.zern@schweizeraktien.net

+41 79 774 44 30

About schweizeraktien.net

schweizeraktien.net ag operates schweizeraktien.net, a leading information and networking platform for Swiss small- and mid-cap companies. Through investor conferences and digital formats, the company fosters dialogue between corporates and investors. Its mission is to make SME equities more visible in the capital markets.